Terms ending in 2041
Every in-force patent on CureVac AG's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,241,493 | Coronavirus Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,471,525 | Coronavirus Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,576,966 | Coronavirus Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,596,686 | Coronavirus Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,964,011 | Coronavirus Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,964,012 | Coronavirus Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 12,194,089 | Coronavirus Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 12,390,523 | Coronavirus Vaccine In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,920,174 | RNA Analysis by Total Hydrolysis and Quantification of Released Nucleosides In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,872,280 | RNA vaccine against SARS-CoV-2 variants In force · Medium confidence | GlaxoSmithKline Biologicals S.A. | In force | Medium confidence | |
| 1 more term end in 2041 · Pro | |||||
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11.
9 of these are in force and held by CureVac AG.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.